Christopher Nelson - 06 Feb 2024 Form 4/A Insider Report for QSAM Biosciences, Inc. (QSAM)

Role: EVP Corp Dev & General Counsel
Signature: /s/ Christopher Nelson
Issuer symbol: QSAM
Transactions as of: 06 Feb 2024
Transactions value $: $0
Form type: 4/A
Filing time: 14 Feb 2024, 16:43:03 UTC
Date Of Original Report: 13 Feb 2024
Previous filing: 23 Jun 2023
Next filing: 02 May 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	QSAM	Common Stock	Conversion of derivative security	$26,049	+8,683	+5.01%	$3^*	182,000	06 Feb 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	QSAM	Series B Convertible Preferred Stock	Conversion of derivative security	-$26,049				0	06 Feb 2024	Common Stock	8,683	$3	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Correction to footnote: On February 13, 2024, the reporting person filed a Form 4 which inadvertently reported in footnote 1 that the date of the Exchange Agreements between the Issuer and all the Series B stockholders was 11/18/2023. It is hereby corrected that the Exchange Agreements were entered into between the dates of 10/16/2023 and 10/23/2023.